You have legal rights – contact us today for a free case review.
Kidney patients who undergo MRIs or MRAs and who are injected with the contrast agent Gadolinium are at risk for developing a serious and fatal skin disorder. If you or a loved one developed Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy (NSF/NFD) after an MRI, you have legal rights and are urged to contact our lawyers for a FREE legal consultation. Please fill out the form on this page and someone will contact you immediately.
Magnetic Resonance Angiography uses higher doses of gadolinium-containing contrast agents than MRI. MRA is a procedure that utilizes magnetic resonance imaging to take pictures of blood vessels. During the procedure, the gadolinium-containing agent is injected into the patient so that the blood vessels can be clearly seen.
The FDA is examining cases of Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy (NSF/NFD) that occurs in patients with kidney failure following exposure to gadolinium during MRA tests. The FDA has received reorts of 25 cases of NSF/NFD in patients with kidney failure who received Omniscan. The FDA has warned that gadolinium contrast agents should not be used in patients with kidney failure unless absolutely necessary and that if kidney failure patients do receive gadolinium contrast MRA, they undergo dialysis immediately.
Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy (NSF/NFD) is a newly-identified disease that was noted in 1997. It typically occurs in patients with kidney failure along with high levels of acid in body fluids (acidosis). Patients with NSF/NFD have tight and rigid skin making it difficult to bend joints. NSF/NFD may also result in fibrosis, or scarring, of body organs resulting in the inability of body organs to work properly and can lead to death. Diagnosis of NSF/NFD is done by looking at a sample of skin under a microscope.
Get the Flash Player to see this player.
Click here to listen to other Mark & Associates P.C. podcasts